AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02012088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCOMP
Description: Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
Study NCT02012088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RCHOP
Description: Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
Study NCT01753674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
Study NCT04039776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography (CBCT)
Description: Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism.
Study NCT00524797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Profonycia
Study NCT02950961 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative Care for Women Veterans
Description: This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators offered in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators trained appropriate MH providers in CALM and studied the ways in which the intervention needs to be tailored to women Veterans.
Study NCT05976451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: melatonin with collagen matrix
Description: (CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)
Study NCT05976451 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft (CTG)
Description: control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
Study NCT00002762 — intervention group
Intervention type: BEHAVIORAL
Intervention: patient interviewing to obtain menstrual history
Study NCT00002762 — intervention group
Intervention type: PROCEDURE
Intervention: blood sampling
Study NCT02258178 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flucelvax (cTIV)
Description: vaccine exposure in routine care (no vaccination per protocol)
Study NCT03055988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Fixed Dose Combination
Study NCT00003958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01114607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK modified-process: formulation D
Description: GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
Study NCT01114607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK tablet: formulation E
Description: GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
Study NCT02229474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CST Intervention
Description: The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
Study NCT01673230 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery for ventricular dysfunction
Description: For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
Study NCT01314937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Single-dose 500 mg mebendazole tablet
Study NCT01314937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Study NCT01314937 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Study NCT01228019 — intervention group
Intervention type: DRUG
Intervention: Niacin (+) laropiprant
Description: Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
Study NCT01584817 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telephone education
Description: A repeated instruction by telephone on the day before colonoscopy was conducted
Study NCT00797589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES
Description: 20ml/kg as prime fluid
Study NCT00797589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Study NCT03258203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Overweight Using Novel Dietary Strategies
Description: The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
Study NCT00681031 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX®
Description: One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
Study NCT05410964 — intervention group
Intervention type: DEVICE
Intervention: VIO System
Description: To investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health
Study NCT03252743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based internet-delivered CBT
Description: The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises.
Study NCT02647801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation).
Study NCT00473460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
Study NCT00473460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules orally once daily for 5 days every 8 weeks.
Study NCT02756884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LoFU and aADSC
Description: Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
Study NCT02756884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adipose derived stem cells
Description: control arm will only received the adipose derived stem cells.
Study NCT03504683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early TRE
Description: Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
Study NCT03504683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-day TRE
Description: Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
Study NCT03504683 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Schedule
Description: Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
Study NCT01141205 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFO-18
Description: 18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
Study NCT01141205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1.2 ml saline intramuscularly
Study NCT01915745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of SMS
Description: Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
Study NCT01499446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X (fluticasone furoate) 100mcg Morning
Description: GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
Study NCT01499446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW685698X (fluticasone furoate) 100mcg Morning
Description: GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
Study NCT01660529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT
Study NCT00761033 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: music
Study NCT00761033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music
Study NCT04056962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
Study NCT04056962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus ointment
Description: topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
Study NCT02251782 — intervention group
Intervention type: DEVICE
Intervention: Epi proColon Test
Description: Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
Study NCT02251782 — intervention group
Intervention type: DEVICE
Intervention: Fecal Immunochemical Test (FIT)
Description: Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
Study NCT00942422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study NCT00942422 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
Study NCT00942422 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein analysis
Description: Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
Study NCT00942422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
Study NCT04360889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin)
Description: Micronised purified flavonoid fraction (diosmin+flavonoids expressed as hesperidin) is prescribed at a dose of 1000 mg / day Tocopherol is prescribed at a dose of 400 ME/ day
Study NCT04360889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocopherol
Description: patients with lower limb lymphedema receiving conservative therapy (elastic compression, to which are added preparations with antioxidant endotheliotropic activity (Tocopherol-400 IU/day)
Study NCT04360889 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Elastic compression
Description: patients with lower limb lymphedema receiving conservative therapy that includes only the use of elastic compression
Study NCT00784160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
Description: Lactic Acid
Study NCT01614951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion of the lungs
Description: Pulmonary perfusion with oxygenated blood during ECC.
Study NCT01614951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTK Custodiol
Description: Pulmoplegia before ECC.
Study NCT01614951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard ECC
Description: ECC after standard procedure
Study NCT02509195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq
Description: Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
Study NCT01499446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X (fluticasone furoate) 100mcg Evening
Description: GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
Study NCT01499446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW685698X (fluticasone furoate) 100mcg Evening
Description: GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
Study NCT01499446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X (fluticasone furoate) 250mcg Evening
Description: GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
Study NCT01499446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW685698X (fluticasone furoate) 250mcg Evening
Description: GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
Study NCT01499446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaled twice daily (morning and evening) for 28 days
Study NCT03903211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: Imaging for evaluating the accumulation of abnormal tau protein in the brain
Study NCT03958695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)
Description: A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
Study NCT03958695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator mid-urethral tape, Urosling (Lintex, LLC)
Description: A transobturator tension-free mid-urethral sling
Study NCT02269709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARFI Ultrasound
Description: This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
Study NCT02967965 — intervention group
Intervention type: OTHER
Intervention: Imagery
Description: MRI at year 3
Study NCT00890604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stepwise normothermia protocol
Description: Use of standard care interventions in a protocolized/step-wise fashion instead of ad hoc based on nurse decision making which may include antipyretics, physical cooling measures.
Study NCT01295736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil 20 mg TID per os during 90 days
Study NCT01295736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pills TID per os during 90 days
Study NCT03765151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
Study NCT03765151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orthodontic retention
Description: All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
Study NCT03765151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: orthodontic retention
Description: All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
Study NCT00111540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
Study NCT03306641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact Lens
Description: Daily disposable contact lens
Study NCT03306641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A
Description: Focus Dailies All Day Comfort contact lens (nelfilcon A)
Study NCT00499408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)